UCL Cancer Institute
The UCL Cancer Institute
The UCL Cancer Institute is located in the heart of London and is part of University College London (“UCL”), which is consistently ranked among the top 20 universities in the world. It was established in 2007 and is the hub for cancer research at UCL. The Institute is part of the Faculty of Medical Sciences within the School of Life and Medical Sciences; this School comprises the largest concentration of biomedical researchers in Europe. The Institute hosts the majority of cancer research at UCL, whilst other cancer research activities across the UCL campus form part of the Cancer Domain.
The Institute is structured as five departments (namely Cancer Biology, Oncology, Haemotology, Pathology and the CR-UK Cancer Trials Centre). The Institute is affiliated with a number of teaching and specialist hospitals in Central London, including University College London Hospitals (which includes UCH and the UCH Macmillan Cancer Centre), the Royal Free Hospital and Great Ormond Street Hospital for Sick Children. Reflecting its focus on translational work, the Institute is also the nucleus for the UCL Cancer Research UK Centre and the UCL Experimental Cancer Medicine Centre.
The overall remit of the Institute is to develop a cancer presence and excellence which rival other major national and international hubs for cancer research.
Particular areas for strength in research within the Institute include stem cell biology, transcription factors, cell cycles, translational immunology, genomics and bioinformatics, mechanisms of chromatin regulation, gene and immunotherapy, viral oncology, drug development and clinical trials.
Professor Chris Boshoff FRCP PhD FMedSci
Director, UCL Cancer Institute, and Chair, UCL Cancer Domain
“We are at the dawn of the most exciting time in the history of cancer research and treatment. New targeted therapies are resulting in major clinical responses, and molecular markers, circulating tumour cells, as well as molecular imaging will be applied to stratify patients to the best therapies, sparing patients unnecessary toxic therapies, and facilitating evaluation of responses early during treatment to determine whether patients are responding to specific therapy.
Molecular profiles, including whole genome sequencing information, will determine in the near future the best treatment for each individual patient, as well as helping to predict the likely outcome and adverse affects.”
Page last modified on 21 may 13 10:03